低成本测序平台用于常染色体显性多囊肾病快速基因分型及其对临床诊疗的影响
研究建立多重PCR panel(MPP)检测441例常染色体显性多囊肾病(ADPKD)患者的6个多囊肾病基因,MPP检出致病变异占65.3%;对32例MPP阴性者追加Sanger测序或定制基因panel,发现20个MPP漏检变异,估计总体假阴性率24.6%、假阳性率9.4%;基因型信息可能影响8.2%分子诊断患者的治疗决策。
要点
- MPP在441例ADPKD患者中检出致病变异占65.3%。
- 32例MPP阴性者追加测序发现20个漏检变异,估计总体假阴性率24.6%、假阳性率9.4%。
- 基因型信息可能影响8.2%分子诊断患者的治疗决策。
核心结论
- MPP可快速、低成本获得基因型信息,并便于扩展panel纳入新致病基因。
- MPP阴性患者需追加PKD1假基因同源区域测序;仅测该区域时假阴性率为3.28%。
- 即使资源有限,获取基因型信息对ADPKD患者的最佳咨询也很重要。
研究设计与样本
- 建立多重聚合酶链反应(PCR)panel(MPP),分析441例ADPKD患者的6个多囊肾病基因(PKD1、PKD2、HNF1B、GANAB、DZIP1L和PKHD1)。
- 对部分患者追加Sanger测序或定制富集基因panel测序。
- 将结果与临床特征结合,评估遗传数据对临床决策的影响。
- 意义未明变异(VUS)在典型ADPKD临床表型下被视为诊断性变异。
主要发现
- 使用MPP在65.3%的患者中检出致病变异。
- 在32例MPP阴性患者中,Sanger测序和定制基因panel发现20个MPP漏检变异,估计总体假阴性率24.6%、假阳性率9.4%。
- 结合临床与遗传数据,基因型信息可能影响8.2%分子遗传学诊断患者的治疗决策。
- 在MPP阴性患者中仅对PKD1假基因同源区域测序,得到的假阴性率为3.28%。
临床怎么用
- MPP可用于ADPKD的快速基因分型,成本较低,且panel可简单扩展以纳入新致病基因。
- MPP阴性病例需追加PKD1假基因同源区域测序。
- 即使资源有限,也应让ADPKD患者获得基因型信息以优化患者咨询。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Autosomal-dominant polycystic kidney disease (ADPKD) is the most common genetic cause of kidney failure. Because of the heterogeneity in disease progression in ADPKD, parameters predicting future outcome are important. The disease-causing genetic variant is one of these parameters. METHODS: A multiplex polymerase chain reaction (PCR)-based panel (MPP) was established for analysis of 6 polycystic kidney disease (PKD) genes (PKD1, PKD2, HNF1B, GANAB, DZIP1L, and PKHD1) in 441 patients with ADPKD. Selected patients were additionally sequenced using Sanger sequencing or a custom enrichment-based gene panel. Results were combined with clinical characteristics to assess the impact of genetic data on clinical decision-making. Variants of unclear significance (VUS) were considered diagnostic based on a classic ADPKD clinical phenotype. RESULTS: Using the MPP, disease-causing variants were detected in 65.3% of patients. Sanger sequencing and the custom gene panel in 32 patients who were MPP-negative revealed 20 variants missed by MPP, (estimated overall false negative rate 24.6%, false-positive rate 9.4%). Combining clinical and genetic data revealed that knowledge of the genotype could have impacted the treatment decision in 8.2% of patients with a molecular genetic diagnosis. Sequencing only the PKD1 pseudogene homologous region in MPP-negative patients resulted in an acceptable false-negative rate of 3.28%. CONCLUSION: The MPP yields rapid genotype information at lower costs and allows for simple extension of the panel for new disease genes. Additional sequencing of the PKD1 pseudogene homologous region is required in negative cases. Access to genotype information even in settings with limited resources is important to allow for optimal patient counseling in ADPKD.
引用
- Lindemann CH, Wenzel A, Erger F, et al. A Low-Cost Sequencing Platform for Rapid Genotyping in ADPKD and its Impact on Clinical Care. Kidney Int Rep. 2022. PMID: 36938073. doi:10.1016/j.ekir.2022.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。